Breaking Finance News

Shore Capital retained Shire PLC (LON:SHP) to Buy in a statement released earlier today.

Shore Capital has retained Shire PLC (LON:SHP) to Buy in a report released on 10/06/2016.

Boasting a price of 5,079.50GBX, Shire PLC (LON:SHP) traded 0.41% higher on the day. With the last stock price close up 11.80% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Shire PLC has recorded a 50-day average of 4,983.50GBX and a two hundred day average of 4,550.18GBX. Volume of trade was down over the average, with 792,308 shares of SHP changing hands under the typical 1,950,430

Performance Chart


With a total market value of 0 GBX, Shire PLC has price-earnings ratio of 31.71 with a one year low of 2,707.19GBX and a one year high of 5,377.00GBX .

A total of 18 brokerages have issued a research note on the company. 6 brokers rating the stock a strong buy, 16 equity analysts rating the company a buy, zero brokerages rating the company a hold, zero brokers rating the stock a underperform, and finally zero equity analysts rating the company a sell with a one year target of 73.73GBX.

About Shire PLC (LON:SHP)

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company's products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.